First lipoprotein A lowering active ingredients in sight

Of the 281 people with elevated lipoprotein A, 227 received injections of olparisan under the skin, and 54 received only placebo injections. At baseline, subjects had a mean lipoprotein A level of 260 nmol/L. 36 weeks later, it had increased slightly in the placebo group. However, in people receiving Oparisan, it dropped by 70 (10 milligrams every 12 weeks) to 100 percent (225 milligrams every 24 weeks), depending on the dose. Levels of two other blood fats also decreased compared to baseline, LDL cholesterol by up to 25 percent and apolipoprotein B by up to 19 percent. Other than injection site reactions, no side effects were observed.

Olparisan belongs to a new class of active substances, siRNA. The abbreviation stands for small interfering RNA. They are short pieces of genetic material in the form of RNA that are designed to specifically inhibit the production of certain proteins in the body’s cells—in this case, apolipoprotein A, the basic component of lipoprotein A.

According to the results of a new study, which were presented at the annual meeting of the American Heart Association (AHA), this method can effectively reduce the elevated level, which is usually inherited. Whether this reduction prevents serious cardiovascular diseases, such as heart attacks, needs to be shown in further studies.

What: DOI 10.1056/NEJMoa2211023

Leave a Comment